Tested Applications
| Positive WB detected in | human red blood cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:3000-1:15000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
67393-1-Ig targets KEL in WB, ELISA applications and shows reactivity with Human samples.
| Tested Reactivity | Human |
| Cited Reactivity | human |
| Host / Isotype | Mouse / IgG2a |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag28192 Product name: Recombinant human KEL protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 70-311 aa of BC050639 Sequence: QNCGPRPCETSVCLDLRDHYLASGNTSVAPCTDFFSFACGRAKETNNSFQELATKNKNRLRRILEVQNSWHPGSGEEKAFQFYNSCMDTLAIEAAGTGPLRQVIEELGGWRISGKWTSLNFNRTLRLLMSQYGHFPFFRAYLGPHPASPHTPVIQIDQPEFDVPLKQDQEQKIYAQIFREYLTYLNQLGTLLGGDPSKVQEHSSLSISITSRLFQFLRPLEQRRAQGKLFQMVTIDQLKEMA Predict reactive species |
| Full Name | Kell blood group, metallo-endopeptidase |
| Calculated Molecular Weight | 83 kDa |
| Observed Molecular Weight | 93 kDa |
| GenBank Accession Number | BC050639 |
| Gene Symbol | KEL |
| Gene ID (NCBI) | 3792 |
| RRID | AB_2882637 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P23276 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for KEL antibody 67393-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The KEL Monoclonal antibody (1C8B6), catalog number 67393-1-Ig, has 2 total citations. Both appear in Science Advances and bioRxiv, from the same research group (Podszywałow-Bartnicka et al.). The studies focus on transcriptional readthrough and alternative splicing programs in chronic myeloid leukemia (CML) cells treated with imatinib, placing the citations within the fields of oncology, RNA biology, and targeted cancer therapy.
| Species | Application | Title |
|---|---|---|
Sci Adv Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib. | ||
bioRxiv Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib. |



